Navigation Links
GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony
Date:1/20/2011

ATLANTA, Jan. 20, 2011 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is one of three recipients of the 2011 Georgia Bio (GaBio) Community Awards.  Dr. Robinson will be honored at the GaBio Annual Awards Dinner to be held Thursday, January 20 at Atlanta's Fox Theater.

Dr. Robinson is the developer of GeoVax's HIV-1 AIDS vaccine technology.  One of the world's leaders in AIDS vaccine research, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University before joining GeoVax, of which she is a co-founder.

Dr. Robinson's early work with HIV vaccines demonstrated that DNA alone would likely not be sufficient to raise protective immunity for HIV.  She combined DNA with protein boosters or live viral-vectored boosters to show that effective control might be achieved through a combination of DNA prime and viral-vectored boosters.  It is these vaccines that GeoVax licensed for commercial development and now has in Phase 2 clinical trials.  Dr. Robinson received her B.A. from Swarthmore College and her PhD in Microbiology from Massachusetts Institute of Technology.

Commenting on the award, Robert T. McNally, Ph.D., President and CEO of GeoVax, said, "We are delighted that Georgia Bio has seen fit to honor Harriet this year.  We at GeoVax have long been aware of her extraordinary talents, and we are lucky to have her on staff as we continue to pursue the development of our preventative and therapeutic HIV vaccines."

Each year, Georgia Bio recognizes individuals, companies or institutions for significant contributions to Georgia's life sciences industry with its GaBio Community Awards.  Georgia Bio (www.gabio.org) is a private, non-profit association representing nearly 300 pharmaceutical, biotech and medical device companies, medical centers, universities, research institutes, medical centers, government groups and other business organizations involved in the development of products that improve health and well-being of people animals and the environment.

Editors note: An image of Dr. Robinson, can be downloaded on irgnews.com.

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents.  Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.  GeoVax’s vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein.  All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines’ safety.  Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV.  For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act, These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.Contact:GeoVax Labs, Inc.Robert T. McNally, President & CEO678-384-7220The Investor Relations Group 212-825-3210 Investor Relations:James Carbonaraor Public Relations:Janet Vasquez
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
2. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
3. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
4. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
5. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
6. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
7. GeoVax Labs Requests pre-IND Meeting With FDA
8. GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
9. GeoVax Labs, Inc. Provides Clinical Studies Update
10. GeoVax Labs, Inc. Announces Resignation of Director
11. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review and report looks at ... focus on the economic effects in countries that are major global commodity exporters and ... the resultant risk of low level presence (LLP) puts large volumes of trade worth ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):